Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 9/20 | 0.59 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.55 |
| ▸ | EGFR | P00533 | 3/20 | 0.55 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.54 |
| ▸ | AURKA | O14965 | 1/20 | 0.54 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.53 |
| ▸ | MET | P08581 | 1/20 | 0.51 |
| ▸ | BRAF | P15056 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3945122 | 0.92 | KDR (0.60) | KDRMAPK14EGFRAURKBAURKA | |
| SCHEMBL3953290 | 0.92 | KDR (0.60) | KDRMAPK14EGFRAURKBAURKA | |
| SCHEMBL3947988 | 0.87 | AURKB (0.71) | KDRMAPK14EGFRAURKBAURKA | |
| SCHEMBL3947622 | 0.87 | KDR (0.73) | KDRMAPK14EGFRAURKBAURKA | |
| SCHEMBL3949004 | 0.86 | KDR (0.73) | KDRMAPK14EGFRAURKBAURKA | |
| SCHEMBL3949424 | 0.85 | KDR (0.61) | KDRMAPK14EGFRAURKBAURKA | |
| SCHEMBL3949732 | 0.83 | KDR (0.72) | KDRMAPK14EGFRAURKBAURKA | |
| SCHEMBL3953271 | 0.83 | KDR (0.73) | KDRMAPK14EGFRAURKBAURKA | |
| SCHEMBL3946532 | 0.82 | KDR (0.74) | KDREGFRBRAF | |
| SCHEMBL3949215 | 0.82 | KDR (0.60) | KDRMAPK14EGFRAURKBAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7514460-B2 | Benzazole analogues and uses thereof | 4SC AG (DE) | 2009-04-07 | — | — | US | disclosed |
| US-7514460-B2 | Benzazole analogues and uses thereof | 4SC AG (DE) | 2009-04-07 | — | — | US | disclosed |
| US-7514460-B2 | Benzazole analogues and uses thereof | 4SC AG (DE) | 2009-04-07 | — | — | US | disclosed |
| EP-1674467-A1 | 2,5- and 2,6-disubstituted benzazole derivatives useful as protein kinase inhibitors | 4SC AG (DE) | 2006-06-28 | — | — | EP | disclosed |
| US-20060135782-A1 | Benzazole analogues and uses thereof | 4SC AG (DE) | 2006-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135782-A1 | Benzazole analogues and uses thereof | DCK, SBK3, DAPK3 | KDR 1657/4885MAPK14 202/4885EGFR 437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.